Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: tom jones who wrote (2652)	9/3/1999 12:22:00 AM
From: ted indig	Respond to of 4676

please bear in mind that many of the drugs that are effective for crohns also work for "ulcerative colitis".the market for ulcerative colitis probably is equal to that of crohns. off label use for uc would likely be substantial.

To: tom jones who wrote (2652)	9/3/1999 12:47:00 AM
From: Sleepman	Read Replies (1) \| Respond to of 4676

I have a couple of thoughts regarding this drug, although I have not yet decided to buy ISIP. I think that this drug has alot of potential to be a broad spectrum antiinflammatory agent. It addresses one of the central aspects of inflammation, and crohns is just a discrete target to focus. It should also do what Embrex does, only later in the pathway. I am not sure where to buy this stock, but if 2302 works out with a good side effect profile, we might be able to say adios to predisone with all of its nasty effects. Just a few thoughts. Dan